Dr. Gary Feldman, Principal Investigator for the MRM-3379 Phase 2 clinical trial at the Irvine, California site, standing with an individual with Fragile X syndrome.

Recruiting: Mirum Launches Clinical Trial of MRM-3379 for Fragile X Syndrome

December 1, 2025

Mirum’s MRM-3379 Phase 2 trial builds on FRAXA-funded PDE4D research and is now enrolling males ages 13–45 with Fragile X syndrome. View eligibility and study sites.

Read More »

FRAXA Research Foundation Joins COMBINEDBrain Consortium for Fragile X Biomarker Research

December 1, 2025

Help accelerate research on Fragile X syndrome biomarkers by contributing samples to the COMBINEDBrain Consortium’s project.

Read More »
Neural Markers of Fragile X: A Powerful New Tool for Clinical Trials

Recruiting: BRIDGE Study (BRain Indicators of Developmental Growth)

March 7, 2022

This study from the Wilkinson Lab at Boston Children’s Hospital is investigating how differences in brain activity affect learning, language and behavior in children with Fragile X syndrome, Down syndrome, and Autism Spectrum Disorder. One of the goals is to find brain markers that predict cognitive, language, and behavioral difficulties in these groups. Another goal is to better understand the differences in brain activity between young children with and without Fragile X and Down Syndrome, and whether these differences are similar in children with Autism Spectrum Disorder.

Read More »

Recruiting: Clinical Study of Non-Invasive EEG for Children Ages 2-7

March 5, 2022

Dr. Carol Wilkinson, MD PhD at Boston Children’s Hospital is recruiting children ages 2-7 years with Fragile X syndrome to participate in a study of EEG.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (43)